Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In intraperitoneal, subcutaneous, and orthotopic injection models, MUC20 knockdown decreased tumour growth in immunodeficient mice.
|
29993037 |
2018 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
MUC20 expression was assessed in tissue microarray and tumor specimens of EOC patients by immunohistochemistry.
|
26616226 |
2016 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
IHC was conducted to examine the expression of selected target markers MUC4, MUC13, and MUC20 in 186 ESCC resection samples and the relationships between their expression and tumor regression grade was analyzed.
|
26673820 |
2016 |
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, MUC20 overexpression enhanced EGF-mediated migration and invasion, suggesting a critical role of EGFR in MUC20-mediated effects.
|
23262208 |
2013 |
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
MUC20 knockdown with siRNA decreased cell viability, as well as migration and invasion induced by PSCs in HPAC and HPAF-II cells.
|
29993037 |
2018 |
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
MUC20 overexpression significantly enhanced EOC cell migration and invasion, but not viability.
|
26616226 |
2016 |
Malignant neoplasm of endometrium
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
High levels of MUC20 expression in EC tumors were correlated with an unfavorable histologic subtype.
|
23262208 |
2013 |
Malignant neoplasm of endometrium
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study was performed to explore the effect of MUC20 in endometrial cancer (EC).
|
30784116 |
2019 |
IGA Glomerulonephritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
These characteristics suggest that the production of MUC20 is correlated with development and progression of IgAN and other renal injuries.
|
14565953 |
2004 |
IGA Glomerulonephritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of the alleles and genotypes of MUC20 VNTR polymorphisms did not differ between patients with IgAN and healthy controls.
|
16508246 |
2006 |
Squamous cell carcinoma of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
IHC was conducted to examine the expression of selected target markers MUC4, MUC13, and MUC20 in 186 ESCC resection samples and the relationships between their expression and tumor regression grade was analyzed.
|
26673820 |
2016 |
Squamous cell carcinoma of esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expression of MUC13 and MUC20 in ESCC mainly occurred in the cytoplasm.
|
26323930 |
2015 |
Endometrial Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study was performed to explore the effect of MUC20 in endometrial cancer (EC).
|
30784116 |
2019 |
Endometrial Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
High levels of MUC20 expression in EC tumors were correlated with an unfavorable histologic subtype.
|
23262208 |
2013 |
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
High expression of MUC20 drives tumorigenesis and predicts poor survival in endometrial cancer.
|
30784116 |
2019 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Mucin (MUC) 20 has recently been implicated to play a role in human carcinogenesis.
|
26616226 |
2016 |
Ulcerative Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis.
|
26770020 |
2015 |
Cystic Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Regions on chr3q29 (MUC4/MUC20; P=3.3 × 10(-11)), chr5p15.3 (SLC9A3; P=6.8 × 10(-12)), chr6p21.3 (HLA Class II; P=1.2 × 10(-8)) and chrXq22-q23 (AGTR2/SLC6A14; P=1.8 × 10(-9)) contain genes of high biological relevance to CF pathophysiology.
|
26417704 |
2015 |
Immunologic Deficiency Syndromes
|
0.010 |
Biomarker
|
group |
BEFREE |
In intraperitoneal, subcutaneous, and orthotopic injection models, MUC20 knockdown decreased tumour growth in immunodeficient mice.
|
29993037 |
2018 |
Lupus Nephritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mouse MUC20 mRNA was expressed in the epithelial cells of proximal tubules, and the expression increased dramatically with the progression of lupus nephritis in the kidney of MRL/MpJ-lpr/lpr mice.
|
14565953 |
2004 |
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our results suggest that MUC20 enhances aggressive behaviors of EOC cells by activating integrin β1 signaling and provide novel insights into the role of MUC20 in ovarian cancer metastasis.
|
26616226 |
2016 |
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analysis using the Gene Expression Omnibus public microarray database indicated higher DUSP28, MUC1, MUC4, MUC5B, MUC16 and MUC20 messenger RNA (mRNA) levels in pancreatic cancers compared with normal pancreas tissues.
|
27230679 |
2016 |
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MUC20 overexpression significantly enhanced EOC cell migration and invasion, but not viability.
|
26616226 |
2016 |
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MUC20 high expression was associated with age, histology, positive peritoneal cytology, advanced stage, and lymph node metastasis (P < 0.05).
|
30784116 |
2019 |
Pancreatic Ductal Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
|
29993037 |
2018 |